Next Article in Journal
Rabbit Hemorrhagic Disease Virus Detected in Pico, Azores, Portugal, Revealed a Unique Endemic Strain with More Than 17 Years of Independent Evolution
Next Article in Special Issue
Filovirus RefSeq Entries: Evaluation and Selection of Filovirus Type Variants, Type Sequences, and Names
Previous Article in Journal
Phages Preying on Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis: Past, Present and Future
Previous Article in Special Issue
Analysis of Determinants in Filovirus Glycoproteins Required for Tetherin Antagonism
Open AccessMeeting Report

Challenges, Progress, and Opportunities: Proceedings of the Filovirus Medical Countermeasures Workshop

1
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
2
Medical Countermeasure Systems, Department of Defense, Ft. Detrick, Frederick, MD 21702, USA
3
Biodefense Advanced Research and Development Authority, Assistant Secretary for Preparedness and Response, Department of Health and Human Services, Washington, DC 20201, USA
4
Medical Countermeasure Systems, Department of Defense, Fort Belvoir, VA 22060, USA
*
Author to whom correspondence should be addressed.
Viruses 2014, 6(7), 2673-2697; https://doi.org/10.3390/v6072673
Received: 22 April 2014 / Revised: 1 July 2014 / Accepted: 1 July 2014 / Published: 9 July 2014
(This article belongs to the Collection Advances in Ebolavirus, Marburgvirus, and Cuevavirus Research)
On August 22–23, 2013, agencies within the United States Department of Defense (DoD) and the Department of Health and Human Services (HHS) sponsored the Filovirus Medical Countermeasures (MCMs) Workshop as an extension of the activities of the Filovirus Animal Non-clinical Group (FANG). The FANG is a federally-recognized multi-Agency group established in 2011 to coordinate and facilitate U.S. government (USG) efforts to develop filovirus MCMs. The workshop brought together government, academic and industry experts to consider the needs for filovirus MCMs and evaluate the status of the product development pipeline. This report summarizes speaker presentations and highlights progress and challenges remaining in the field. View Full-Text
Keywords: Ebola; Sudan; ebolavirus; Marburg virus; marburgvirus; Filoviridae; filovirus medical countermeasures; Filovirus Animal Non-clinical Group; FANG Ebola; Sudan; ebolavirus; Marburg virus; marburgvirus; Filoviridae; filovirus medical countermeasures; Filovirus Animal Non-clinical Group; FANG
MDPI and ACS Style

Hirschberg, R.; Ward, L.A.; Kilgore, N.; Kurnat, R.; Schiltz, H.; Albrecht, M.T.; Christopher, G.W.; Nuzum, E. Challenges, Progress, and Opportunities: Proceedings of the Filovirus Medical Countermeasures Workshop. Viruses 2014, 6, 2673-2697.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop